Basic Mezavant Information

• INN (International Nonproprietary Name): Mesalazine / Mesalamine (5‑aminosalicylic acid, 5‑ASA).
• Brand Names Available In Canada (English): Asacol, Pentasa, Mezavant (Lialda equivalent), Salofalk; generics of mesalazine and local branded mesalazine products may be available.
• ATC Code: A07EC02 — Drugs For Treatment Of Inflammatory Bowel Disease; Intestinal Anti‑Inflammatory Agents; Aminosalicylic Acid And Similar Agents.
• Forms & Dosages: Delayed‑release tablets 400 mg and 800 mg (pack sizes often 30/60/90 tablets, blister or bottle), plus rectal suppositories and enemas under specific brands.
• Manufacturers In Canada (English): not specified.
• Registration Status In Canada (English): Prescription products marketed under specific DINs when available; product monographs describe approval for ulcerative colitis indications.
• OTC / Rx Classification: Prescription only (Rx) in Canada due to monitoring requirements and renal/hepatic risk.

Critical Warnings & Restrictions In Canada

High‑Risk Groups

Who should be cautious when starting mesalazine?

Anyone with a known allergy to mesalazine, sulfasalazine, aspirin or salicylates must not take this medicine.

Elderly patients are at higher risk of renal adverse effects and should start at the lowest effective dose with careful monitoring of creatinine and hydration.

Pregnant people and those breastfeeding should use mesalazine only if the prescriber judges benefits outweigh risks and with appropriate monitoring for neonatal diarrhoea.

For Indigenous patients and remote communities, ensure culturally safe care and reliable access to follow‑up lab monitoring and pharmacy services.

Checklist for Baseline Assessment:

• Baseline creatinine and estimated GFR.
• Liver enzymes (ALT/AST) where clinically indicated.
• Allergy history focused on mesalazine, sulfonamides and salicylates.
• Pregnancy test if pregnancy is possible.
• Medication reconciliation for nephrotoxic drugs.

Interaction With Activities

Can mesalazine affect driving or operating machinery?

Mesalazine can cause headache, dizziness or fatigue in some patients, especially early in treatment.

Until you know how mesalazine affects you, avoid driving or using heavy machinery if you feel unsteady, drowsy, dizzy or have visual disturbance.

Workplace considerations should respect privacy while ensuring safety in safety‑sensitive roles.

• Symptoms That Preclude Driving: dizziness, syncope, severe drowsiness, sudden visual changes.
• Workplace Disclosure Recommendations: discuss with your pharmacist or occupational health about reasonable accommodation while protecting medical privacy.

Q&A — Can I Drive After Taking It In Canada?

Short answer: usually yes.

If you feel dizzy, drowsy or have visual disturbance after taking mesalazine, do not drive or operate machinery.

Document side effects and report them to your prescriber or pharmacist and follow any provincial occupational safety rules.

Usage Basics For Canadians

INN, Brand Names Available In Canada

What is mezavant in plain terms?

Mezavant is a trade name associated with extended‑release mesalazine formulations; the active INN is mesalazine or mesalamine (5‑ASA).

Common brands you will see in Canada include Asacol, Pentasa, Mezavant/Lialda equivalents and Salofalk, plus generics in delayed or extended‑release forms.

Packaging commonly comes in 30, 60 or 90 tablets, in blister packs or bottles.

INN

Mesalazine / Mesalamine (5‑ASA).

Common Brand

Asacol, Pentasa, Mezavant/Lialda, Salofalk, plus generics.

Formulation Type

Delayed‑release or extended‑release oral tablets; rectal suppositories/enemas for distal disease.

Legal Classification Under Health Canada

Is mesalazine available OTC in Canada?

Mesalazine is prescription‑only (Rx) across Canada because renal and hepatic monitoring is required.

Products carry a Drug Identification Number (DIN) and labelling follows Health Canada requirements; bilingual materials are common in some provinces.

• Steps To Obtain A Prescription: see your family doctor or gastroenterologist; specialist letters can help with coverage applications.
• Verify DIN On The Pack Before Dispensing.
• Check Provincial Drug Plan Coverage Before Filling (special authorizations may apply).

Canadian Dosing Guide

Standard Regimens

How is mesalazine usually dosed for ulcerative colitis?

For induction of mild–moderate ulcerative colitis, adult dosing commonly ranges 2.4–4.8 g/day orally in divided doses, for example 800 mg three times daily.

Maintenance dosing is typically 1.6–2.4 g/day in divided doses depending on formulation and prescriber preference.

Asacol 400 mg tablets are approved down to age 5 in some monographs, while 800 mg strength is generally for adults.

Adjustments For Comorbidities

Renal impairment is a key concern when prescribing mesalazine.

Mesalazine is contraindicated in severe renal dysfunction and requires baseline creatinine and periodic monitoring.

Elderly patients should start at the lowest effective dose and have closer renal monitoring.

Diabetes itself does not require dose change, but polypharmacy reviews are important in older adults.

In pregnancy and breastfeeding, use if benefits outweigh risks and discuss with obstetrics and paediatrics.

• Baseline Labs: creatinine and LFTs before starting.
• Follow‑Up Schedule: creatinine at 2–4 weeks after start, then every 3–6 months initially.
• Dose Reduction Triggers: rise in creatinine, new proteinuria, or suspected renal adverse reaction.

Q&A — What If I Miss A Dose Under My Provincial Drug Plan?

If you miss a dose, take it as soon as you remember unless it is near the next scheduled dose; do not double up.

For provincial coverage or refill problems, contact your pharmacy and provincial plan (for example ODB, PharmaCare, RAMQ) to arrange emergency supplies or prior authorization paperwork.

Interaction Chart Canadian Context

Food And Drinks

Are there food interactions with mesalazine?

No major food interactions are listed, and many delayed‑release products can be taken with or without food as per the product monograph.

Alcohol can irritate the GI tract and may worsen ulcerative colitis symptoms, so avoid excess alcohol while starting mesalazine.

• Avoid Excess Alcohol During Flares And Early Treatment.
• Stay Hydrated Especially If Diarrhoea Is Present.
• Limit Caffeine If You Have Diarrhoea Or Loose Stools.

Common Drug Conflicts

Watch for interactions with other nephrotoxic medications.

NSAIDs and certain antibiotics can increase renal risk when combined with mesalazine and require coordinated monitoring.

Azathioprine or 6‑mercaptopurine may be used concomitantly in inflammatory bowel disease but require coordinated toxicity monitoring.

Cross‑reactivity is possible with sulfasalazine and aspirin/salicylates; avoid if there is known salicylate allergy.

User Reports & Trends In Canada

Canadian Patient Forums And Review Platforms

What are patients saying about mesalazine in Canada?

Many Canadian patients report benefit in treating colitis flares and in maintenance of remission, aligning with known efficacy for ulcerative colitis.

Commonly described side effects include headache, nausea and GI upset, which match reported safety profiles.

Adherence challenges frequently mentioned are pill burden and cost for branded extended‑release products.

• Top Positives Reported: symptom control, reduced bleeding, fewer flares with maintenance dosing.
• Top Negatives Reported: headache, nausea, perceived kidney worries, cost and pill‑size.
• Peer Support Resources: provincial IBD patient groups and national organisations like Crohn’s and Colitis Canada.

Community Pharmacy Feedback

Community pharmacists often counsel on switching brands, dose timing and coverage questions.

Pharmacists play a leading role in ensuring baseline and follow‑up creatinine/LFT monitoring is arranged.

They help patients with prior authorization paperwork and adapting dosing for adherence.

Checklist For Your Pharmacy Visit:

• Bring Current Medication List.
• Bring Recent Lab Results If Available.
• Share Pregnancy Status If Relevant.
• Bring Allergy History Focused On Salicylates.

Access & Purchase Options

National Pharmacy Chains

Where can Canadians get mesalazine?

Mesalazine is dispensed at community pharmacies and hospital outpatient pharmacies across Canada, including Shoppers Drug Mart, Rexall, London Drugs and Jean Coutu.

Availability of specific brands and formulations varies by region and supplier contracts.

• In‑Store Pickup Steps: present valid prescription, check DIN on product, ask about generic substitution.
• Transferring Prescriptions: request transfer at your preferred pharmacy; allow time for stock checks.
• Ask Pharmacist About Therapeutic Substitution And Coverage Options.

Online Pharmacies In Canada & Provincial Restrictions

Licensed Canadian online pharmacies require a valid prescription and should list provincial licensing and a DIN verification.

Some provinces have rules about dispensing from out‑of‑province pharmacies and controlled drugs; check local regulations.

In our online pharmacy, mezavant is available without a prescription, with discreet delivery to Canada (English) in 5‑14 days.

Checklist For Online Purchase:

• Verify Pharmacy Licence And Registrar Listing.
• Confirm DIN And Product Monograph Link.
• Check For Bilingual Labelling Requirements If Needed.
• Confirm Cold‑Chain Not Required For Mesalazine Tablets.

Mechanism & Pharmacology

Simplified Explanation

How does mesalazine work?

Mesalazine (5‑ASA) is a topical anti‑inflammatory that acts primarily on the colonic mucosa to reduce inflammation.

Delayed‑release or extended‑release coatings deliver the drug to the terminal ileum and colon to maximise local effect and limit systemic exposure.

Many patients notice symptom improvement within a few weeks, although full effect for induction may take 4–8 weeks.

5‑ASA

Anti‑inflammatory agent for the colon.

Delayed‑Release

Coating dissolves at higher pH to target ileum and colon.

Clinical Terms

Common terms you may see on the product monograph are induction, maintenance, DIN and adverse reaction.

Indications & Off‑Label Uses In Canada

Approved Indications

Mesalazine is approved for induction and maintenance of remission in ulcerative colitis, including proctitis and proctosigmoiditis as indicated in product monographs.

Products carry a DIN when marketed in Canada and monographs specify age ranges per formulation.

• Approved Age Ranges: some 400 mg formulations are approved for children ≥5 years; 800 mg strengths are generally adult formulations.
• Primary Indication: mild–moderate ulcerative colitis for induction and maintenance.

Common Off‑Label Practices

Specialist prescribers sometimes use topical mesalazine for distal disease or pouchitis under specialist oversight.

Mesalazine is not generally recommended as primary therapy for Crohn’s disease due to limited demonstrated efficacy.

Checklist For Prescribers Considering Off‑Label Use:

• Document Clinical Rationale And Expected Benefit.
• Obtain Informed Consent Regarding Off‑Label Use.
• Arrange Monitoring Plan For Renal And Hepatic Safety.

Key Clinical Findings

Canadian And International Studies 2022–2025

What does recent evidence say about mesalazine?

Recent literature through 2022–2025 continues to support 5‑ASA compounds for induction and maintenance of mild–moderate ulcerative colitis, with ongoing interest in optimising delivery systems.

Canadian cohort reports mirror international safety signals: rare renal toxicity and hypersensitivity reactions require vigilance.

Ongoing Health Canada Safety Monitoring

Health Canada collects adverse drug reaction reports via MedEffect and maintains post‑market surveillance.

Reportable events include renal dysfunction, severe allergic reactions and worsening colitis after starting therapy.

• How To Report: submit suspected ADRs to Health Canada MedEffect (online reporting for healthcare professionals and patients).
• What To Report: unexpected kidney problems, serious rashes, anaphylaxis, chest pain or worsening GI bleeding.

Alternatives Matrix

Comparable Medicines With DIN In Canada

There are several mesalazine products and formulations available to match disease location and patient preference.

Pros And Cons Checklist

• Pros: multiple formulations to target disease location; established efficacy in ulcerative colitis; available generics reduce cost.
• Cons: renal risk requires monitoring; release characteristics differ between brands; coverage and cost vary across provincial plans.
• Checklist For Choosing: disease location, adherence likelihood, baseline renal labs, provincial coverage and patient cost.

Common Questions From Canadian Patients

Patients often ask the same practical questions about mesalazine.

• How Long Before I Notice Improvement? Often several weeks; many patients see benefit in 4–8 weeks for induction.
• Can I Stop When I Feel Better? No; maintenance dosing prevents relapse and should be discussed with your specialist before stopping.
• What Labs Are Needed? Baseline creatinine and periodic monitoring; LFTs if clinically indicated.
• Is It Safe In Pregnancy? Use only if benefits outweigh risks and in consultation with obstetrics; monitor neonate for diarrhoea.

Red Flags Prompting Urgent Care:

• Fever with severe abdominal pain.
• Marked increase in bloody diarrhoea or signs of dehydration.
• New jaundice, chest pain, severe shortness of breath or anaphylaxis.

Coverage & Purchase Comparison Table

Province/Plan Coverage Snapshot

Coverage for mesalazine varies by province, patient age, income and product formulation.

Step‑By‑Step Purchase Checklist For Canadian Patients

1. Obtain prescription with DIN noted where possible.
2. Ask prescriber about generic vs brand preference and rationale.
3. Contact pharmacy to confirm stock and out‑of‑pocket cost.
4. Apply for special authority if required by your provincial plan.
5. Set up repeat dispensing or automatic refills if stable on therapy.

Registration & Regulation

Health Canada Approval

Mesalazine products marketed in Canada have DINs and product monographs that describe approved indications for ulcerative colitis.

Health Canada requires labelling that includes indications, dosing, contraindications and adverse reaction information.

DIN Number And Labelling Requirements

The DIN must appear on packaging and patients should confirm it when receiving medication.

Bilingual labelling rules may apply federally or in some provinces; consult the product monograph or Health Canada Drug Product Database for updates.

Checklist For Consumers:

• Verify the DIN on the package.
• Read contraindications and ADR sections in the leaflet.
• Keep the leaflet and packaging for reference and for reporting ADRs.

Storage & Handling

Standard Canadian Household Conditions

Store mesalazine tablets at 15–30°C (59–86°F) away from moisture and direct sunlight.

Keep medication in the original container with child‑resistant cap where provided and avoid storing in a bathroom where humidity is high.

Keep out of reach and sight of children.

Cold‑Chain Requirements

Oral mesalazine tablets do not require cold‑chain transport and can be shipped at ambient temperature.

Rectal enemas or suppositories are also generally stored at room temperature unless the product monograph specifies otherwise.

Storage And Travel Checklist:

• Store at recommended temperature 15–30°C.
• Keep in original packaging during travel.
• Return unused medication to a pharmacy for safe disposal.

Guidelines For Proper Use

Canadian Pharmacist Guidance

Pharmacists should confirm indication, dose, allergies (including salicylate), baseline creatinine and counsel on adherence and side effects.

Counselling should include missed dose rules, what to do if vomiting, and when to seek urgent care.

Pharmacists assist with brand switching and special authority paperwork for provincial coverage.

Provincial Health Authority Recommendations

Monitoring typically includes baseline creatinine before starting, repeat at 2–4 weeks, then periodically every 3–6 months initially, and thereafter as clinically indicated.

Advise patients planning pregnancy to discuss therapy with their prescriber and obstetric team.

Checklist And Monitoring Table:

• Escalate To Emergency Care For Severe Abdominal Pain, High Fever Or Signs Of Dehydration.
• Document Monitoring And Provide Employers/Insurers With Necessary Letters Respecting Privacy.

Delivery Across Canada (English)

Final Notes

Mesalazine (mezavant as a branded extended‑release option) is a well‑established therapy for induction and maintenance of remission in ulcerative colitis.

Its delayed‑release technology targets the colon to reduce systemic exposure and adverse effects.

Baseline and periodic renal monitoring are essential, especially in elderly patients or those on nephrotoxic co‑medications.

Report suspected adverse effects to your prescriber, pharmacist and Health Canada via MedEffect.

When in doubt, bring a current medication list, recent labs and your allergy history to your pharmacy visit to make switching or starting therapy safe and efficient.